vimarsana.com
Home
Live Updates
Zymeworks Presents New Data from Multiple Preclinical and Cl
Zymeworks Presents New Data from Multiple Preclinical and Cl
Zymeworks Presents New Data from Multiple Preclinical and Clinical Development Programs at the 2023 American Association for Cancer Research Annual Meeting
● ZW191 demonstrates strong responses in FRα-low expressing patient-derived xenograft models with favorable pharmacokinetic and safety profiles● ZW171 induced potent preferential... | April 18, 2023
Related Keywords
Vancouver ,
British Columbia ,
Canada ,
Florida ,
United States ,
Ireland ,
United Kingdom ,
Orlando ,
American ,
British ,
Diana Papove ,
Jack Spinks ,
Paul Moore ,
Securities Exchange ,
American Association For Cancer Research ,
Nasdaq ,
Program Presentations ,
Corporate Communications ,
Beigene Ltd ,
Zymeworks Inc ,
Exchange Commission ,
Jazz Pharmaceuticals Ireland ,
Additional Multispecific Antibody Therapeutics Program Presentations ,
Eastern Daylight Time ,
Cancer Research ,
Annual Meeting ,
Chief Scientific Officer ,
Therapeutic Antibodies ,
Antibody Drug ,
Clinical Trials ,
Phasei Clinical Trials ,
Webcast Information ,
Jazz Pharmaceuticals Ireland Limited ,
Securities Act ,
Securities Exchange Act ,
Annual Report ,
Drivingt Cells ,
Targeting Solid Tumors ,
Bispecifict Cell Engager Immune ,
Annual Review ,
Cancer Biology ,
Lab Med ,
Zymeworks Inc Stock Exchange ,
News ,
Information ,
Press Release ,
W191 ,
Emonstrates ,
Strong ,
Responses ,
N ,
Expressing ,
Enograft ,
Models ,
Ith ,
Favorable ,
Pharmacokinetic ,
End ,
Safety ,
W171 ,
Induced ,
Otent Zyme Us98985y1082 ,